<DOC>
	<DOCNO>NCT02285985</DOCNO>
	<brief_summary>In research study , Investigators compare effect medication Saxagliptin versus placebo ( similar look pill contain medication ) inflammation body . Research Hypothesis DPP-4 inhibition saxagliptin ( ONGLYZA™ ) reduce adipose tissue inflammation obese individual characterize decrease ) reactive oxygen specie ( ROS ) production , b ) toll-like receptor ( TLR ) NF-kappa B pathway activation , c ) expression pro-inflammatory gene , ) macrophage infiltration , e ) secretion pro-inflammatory factor .</brief_summary>
	<brief_title>Effects Saxagliptin Adipose Tissue Inflammation Humans</brief_title>
	<detailed_description>This randomize , prospective , double-blind study . Randomization Saxagliptin placebo 2:1 fashion . Treatment duration approximately 6 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>1 . Signed Written Informed Consent 1 . Before study procedure perform , subject detail study describe , give write informed consent document read . Then , subject consent participate study , indicate consent sign date informed consent document presence study personnel . 2 . Subjects must able communicate meaningfully investigator legally competent provide inform write consent . 2 . Target Population 1 . Body mass index 27.537.5 kg/m2 2 . Stable body weight ( vary &gt; 10 % last 6 month ) 3 . Age Reproductive Status 1 . Men woman , age 21 70 year . 2 . Women must sterilize hysterectomy postmenopausal acceptable birth control childbearing potential . 3 . Women childbearing potential ( WOCBP ) include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Post menopause define : Amenorrhea ≥12 consecutive month without another cause document serum follicle stimulate hormone ( FSH ) level &gt; 35 mIU/mL , Women irregular menstrual period document serum FSH level &gt; 35 mIU/mL , NOTE : FSH level test required woman ≥62 year old amenorrhea ≥1 year Women hormone replacement therapy ( HRT ) Women use oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence partner sterile ( e.g. , vasectomy ) consider childbearing potential . 1 . Sex Reproductive Status 1 . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 2 . Women pregnant breastfeed 2 . Target Disease Exceptions 1 . Gastrointestinal disease ( include gastrectomy , chronic pancreatitis , bariatric surgery gastroparesis ) 2 . Hepatic disease ( ALT , AST &gt; 2.5 time upper limit normal , high sensitivity CRP ≥1 mg/L ) 3 . Kidney disease ( serum creatinine &gt; 1.6 mg/dl , Creatinine Clearance 50 mL/min ) 4 . Hypertension ( blood pressure &gt; 150/95 mmHg ) Screening mean three consecutive reading perform sit position 5minute resting period . If treatment hypertension recently initiate , subject must clinically stable 4 week prior Screening 5 . Cardiac disease ( myocardial infarction within past year , clinically significant arrhythmia , unstable angina , congestive heart failure , coronary artery bypass surgery within 1 year expect require coronary bypass surgery within 12 month study entry ) . 3 . Medical History Concurrent Diseases 1 . Type 1 diabetes mellitus 2 . Type 2 diabetes mellitus 3 . History diabetic ketoacidosis hyperosmolar nonketotic coma 4 . Malignancy basal cell squamous cell skin cancer 5 . Significant clinical allergic rhinitis asthma , regularly require inhaled corticosteroid and/or antihistamine 4 . Additional Laboratory Test Findings 1 . Hemoglobin &lt; 12 g/dl men , &lt; 11 g/dl woman 2 . Abnormal prothrombin partial thromboplastin time 3 . Clinically abnormal thyroid stimulate hormone ( TSH ) 4 . 2 hour glucose &gt; 170mg/dl standard oral glucose tolerance test ( OGTT ) 5 . Allergies Adverse Drug Reactions . Subjects history serious hypersensitivity reaction saxagliptin , anaphylaxis , angioedema , exfoliative skin condition . 6 . Prohibited Treatments and/or Therapies 1 . Treatment strong systemic cytochrome P450 3A4/5 ( CYP 3A4/5 ) inhibitor 2 . Treatment follow medication screen expect use study : recent systemic glucocorticoid ( 2 week ) , antihyperglycemic agent , antineoplastic agent , transplant medication , drug weight loss , niacin , fibrates , antiretroviral medication 3 . Treatment betablockers , antihistamine inhale corticosteroid within 3 month prior screen 4 . Start change hormonal replacement therapy within 3 month prior screen 7 . Other Exclusion Criteria 1 . Prisoners , subject involuntarily incarcerate 2 . Subjects compulsorily detain treatment either psychiatric physical ( e.g. , infectious disease ) illness 3 . Currently abuse alcohol drug , history alcohol drug abuse investigator 's opinion could cause subject noncompliant ; general history noncompliance medication 4 . Any acute febrile illness within 2 week screen temperature 100°F</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adipose tissue</keyword>
	<keyword>Inflammation</keyword>
	<keyword>.Obesity</keyword>
</DOC>